Partners
Align. Advance. Achieve.
Our partnerships are a cornerstone to our success. They provide expertise, knowledge, funding and in-kind support creating new collaborative opportunities for CPDC.
Our partnership with OICR has enabled the funding of early-stage discovery projects at various academic institutions in Canada, provided regulatory support for clinical trials in Ontario, and allowed us to bring new cancer diagnostic agents to Canadians. The OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, funded by the Government of Ontario. OICR’s research supports more than 1,700 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing.
McMaster University provided supporting infrastructure to the CPDC at the time of its launch in 2008 until 2022. In 2025, McMaster earned a spot as one of the world’s top 150 universities for its strong academic reputation and prestige. McMaster has a long history in Nuclear Research stemming back more the 50 years since the opening of the McMaster Nuclear Reactor (MNR) in 1959. McMaster is recognized as a world-leader in radiation sciences, nuclear engineering, medical isotope and radiopharmaceutical production and research.
Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer the best treatment, while developing tomorrow’s cures through cutting-edge research. In 2016, Dana-Farber and CPDC joined to create the International Probe Development Consortium (IPDC), to combine each party’s expertise in radiopharmaceutical development and cancer research to create novel molecular probes for non-invasive imaging in cancer research, drug development, and patient care.
Lawson Health Research Institute is a large hospital-based research institute located in London, Ontario. Lawson and CPDC have a long standing relationship as co-founders of ARTMS, along with TRIUMF and the BC Cancer Agency. More recently, Lawson has partnered with CPDC as a manufacturing and clinical site for CPDC’s Phase 3 clinical trial for [18F]PSMA-1007, a diagnostic agent for prostate cancer.
TRIUMF Innovations is the interface bridging TRIUMF – Canada’s national particle accelerator laboratory – with the business world. TRIUMF Innovations links cutting-edge science and technology to tangible business opportunities. In 2020, CPDC and TRIUMF Innovations joined forces to co-lead the Canadian Medical Isotope Ecosystem (CMIE), an $80M initiative backed by the Government of Canada’s Strategic Innovation Fund. The CMIE aims to unite a diverse array of stakeholders in the medical isotope sector and accelerate technology development and commercialization.
Innovation, Science and Economic Development Canada (ISED) works with Canadians in all areas of the economy and in all parts of the country to improve conditions for investment, enhance Canada’s innovation performance, increase Canada’s share of global trade and build a fair, efficient and competitive marketplace. ISED’s Strategic Innovation Funding (SIF) has provided CPDC with significant funds to discover and develop next-generation radiopharmaceuticals, as well as expand collaborations and provide funds for company creation, further expanding the Canadian radiopharmaceutical ecosystem.